Insights On Upstream Manufacturing

  1. A Practical Guide To Autologous CAR T Manufacturing 6/19/2026

    Early process decisions shape scalability, consistency, and compliance in autologous CAR T manufacturing. Learn where variability emerges across the workflow and how to plan ahead.

  2. The Invaluable Asset Driving Advanced Therapies Forward 6/19/2026

    Cell therapies are advancing rapidly, but manufacturing delays still limit patient access. Improving operational understanding, reducing risk, and strengthening collaboration may be just as critical.

  3. Achieving High CAR T Cell Transduction Using An Automated Platform 6/19/2026

    Automation is reshaping CAR T manufacturing. A modular, closed approach with digital integration supports efficient workflows while maintaining critical functional performance under GMP conditions.

  4. Accelerating Autologous CAR T Cell Expansion With Automation 6/19/2026

    Scaling CAR T manufacturing demands high expansion without exhaustion. Examine integrated, semi-automated approaches with digital traceability that can improve consistency and preserve cell function.

  5. Evaluating CAR T Cell Therapy Processing 6/19/2026

    Serum-free media is reshaping CAR T manufacturing. Gain insight into how media-agnostic platforms offer the flexibility to adapt workflows without re-optimization, helping teams streamline processes.

  6. Generate Stable High-Producing Clones In 14 Weeks 6/18/2026

    Rising complexity is putting pressure on cell line development. Discover a streamlined approach that enables rapid generation of stable clones with strong titers and long-term consistency.

  7. Where Speed Meets Complexity In Bioprocess Development 6/18/2026

    Bioprocessing faces mounting pressure to compress timelines, especially for mAbs, while complex modalities like bispecifics and gene therapies introduce technical challenges. Process intensification, scale-up translation, and comparability risks remain critical hurdles.

  8. The Scale-Up Of A Transient rAAV8 Production Process 6/18/2026

    New approaches to suspension cell culture and process scaling enable consistent, high-titer rAAV production. Gain insight into a clearer path to scalable manufacturing for gene therapy pipelines.

  9. Elevate Your Protein Production With SynWeave™ 6/15/2026

    Sunit Maity, Ph.D., Senior GM – Biologics Services, introduces an advanced platform that combines state-of-the-art cell line and transposon-based technologies from ExcellGene.

  10. Scalable rAAV9 Production Using Advanced Cell Lines And Bioreactors 6/15/2026

    Progress in gene therapy manufacturing is being driven by improved cell line performance and scalable bioprocessing. See how high-density growth helps streamline development to larger-scale production.